Science
Mechanism of Action
Inhibits tyrosinase enzyme activity through prenylated flavonoids (particularly Kazinol F with IC50 of 0.396 µg/mL) to reduce melanin production, while simultaneously suppressing NF-κB signaling pathways for anti-inflammatory effects and scavenging reactive oxygen species for antioxidant protection
Research
Clinical Evidence
High confidence2%
Key findings
- 01 24-participant clinical trial showing 1.0% Kazinol F significantly reduced UVB-induced pigmentation with efficacy matching hydroquinone
- 02 KFDA registration at 2.0% concentration for functional skin-whitening applications
Transparency
Dusting Analysis
Given the established 1-2% effective concentration range and KFDA registration requirements, formulations below 0.1% likely provide minimal brightening benefit
The Formula
Formulation
Stability
Highly photosensitive and thermolabile; requires protection from light and heat. Stability improved through encapsulation in polymeric microspheres or O/W emulsions with antioxidants.
Synergies
- Antioxidants (for stability)
- Niacinamide
- Vitamin C
Conflicts
- Strong oxidizing agents
- Formulations below pH 4.0
Safety
Safety Profile
Recognized as safe botanical in EU and South Korea. EWG Skin Deep rates as 1 (Low Hazard). No significant safety concerns reported in clinical applications.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A clinically-validated brightening agent that offers hydroquinone-level efficacy with superior tolerability and multi-functional skin benefits.
Related
Similar Ingredients
Finding similar ingredients…